+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 147 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.

Age: 50Years +All GendersPhase 2Phase 3
132 locations
E

Actively Recruiting

Researchers are evaluating the effect of pegloticase given by two different methods along with methotrexate in adults with uncontrolled gout. This phase 3 trial compares subcutaneous under the skin injections of pegloticase at 18 mg every two weeks with intravenous into a vein injections of pegloticase at 8 mg every two weeks, both combined with weekly methotrexate. The main goal is to see which approach better maintains low serum uric acid levels during the sixth month. Participants will be randomly assigned to receive either pegloticase by subcutaneous injection or by intravenous infusion, both administered every two weeks, alongside oral methotrexate taken weekly. The trial is double-blind, meaning neither participants nor researchers know which form of pegloticase is given. Methotrexate is given orally concurrently. Treatment continues through at least six months with ongoing evaluations. During the study, participants will have regular assessments to monitor their response to treatment, including blood tests to measure serum uric acid levels and pegloticase concentrations. Safety will be closely observed, including monitoring for injection site reactions, infusion reactions, and anaphylaxis up to 48 weeks. The primary outcome measures participants who maintain normalized uric acid levels during Month 6, with follow-up lasting up to 48 weeks. Total participation may extend to the study completion in June 2028.

Age: 18Years +All GendersPhase 3
75 locations
M

Actively Recruiting

Researchers are conducting a master protocol study to evaluate multiple independent pain interventions for chronic pain conditions, including osteoarthritis of the knee, chronic low back pain, and diabetic peripheral neuropathic pain. This phase 2, randomized, placebo-controlled trial aims to establish a framework for disease-state addenda and intervention-specific appendices to efficiently study different treatments as they become available. Participants are randomly assigned to receive one of several investigational drugs or a matching placebo. These drugs include LY3016859 administered intravenously and LY3556050, LY3526318, LY3857210, and LY4065967 administered orally. Each intervention-specific appendix operates independently within the overarching study structure, allowing evaluation of various treatments targeting different chronic pain conditions. During the study, participants undergo screening and are monitored for pain levels using specific scales. They maintain consistent use of non-drug pain therapies and discontinue other chronic pain medications except rescue medication. Researchers measure participant allocation to each intervention up to week 8. Safety is monitored through physical exams, ECGs, laboratory tests, and medical history assessments. The study is expected to be completed by April 2027.

Age: 18Years +All GendersPhase 2
64 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
A

Actively Recruiting

Researchers are conducting a multi-center, open-label Phase 1 clinical trial to study ZG006 in people with small cell lung cancer who have not responded to or cannot tolerate existing standard treatments. The study aims to find the maximum tolerated dose and recommended dose for further research, focusing on safety, tolerability, and how the drug behaves in the body. This early phase trial uses a dose escalation design to carefully evaluate dosing levels. ZG006 is given to participants as an intravenous infusion. The trial follows a standard 33 dose escalation approach during which different doses are tested to determine the best dose for future studies. This phase includes monitoring for dose-limiting toxicities and adverse events to assess safety. The study is expected to last about two years for evaluating dosing and safety outcomes. Participants will be monitored closely with various assessments including laboratory tests to detect side effects and the presence of anti-drug antibodies. Researchers will measure how the drug is processed in the body, its concentration over time, and its effects on tumor response. The study includes regular safety checks and follows participants for up to two years to gather comprehensive data on treatment effects and tolerability.

Age: 18Years - 75YearsAll GendersPhase 1
6 locations
P

Actively Recruiting

Researchers are evaluating the safety and tolerability of NKX019, an investigational allogeneic CD19-directed CAR NK cell therapy, in adults with autoimmune diseases such as Lupus Nephritis and Primary Membranous Nephropathy. This Phase 12, open-label, multi-center study uses a dose escalation design to find recommended doses and assess preliminary effects, pharmacokinetics, and pharmacodynamics. Participants undergo a treatment cycle starting with lymphodepletion using fludarabine and cyclophosphamide or cyclophosphamide alone if cytopenic, followed by three doses of NKX019. The study uses a 33 dose escalation to determine safe dosing and includes dose expansion cohorts. The treatment aims to evaluate the impact of NKX019 on autoimmune disease activity and kidney function. During the study, participants are closely monitored for dose-limiting toxicities, adverse events, and lab abnormalities from the first dose until follow-up. Researchers assess kidney response, disease activity scores, and drug levels in blood for up to two years after infusion. Immunogenicity and effects on background therapies are also evaluated. The total participation time varies based on follow-up assessments and treatment response.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
19 locations
S

Actively Recruiting

Researchers are studying the safety and tolerability of NKX019, an investigational allogeneic CD19-directed CAR natural killer CAR NK cell therapy, in adults with autoimmune diseases. This Phase 12 open-label, multi-center, multi-cohort trial uses dose escalation and expansion to evaluate NKX019 in participants with conditions such as systemic sclerosis, idiopathic inflammatory myopathies, ANCA-associated vasculitis, and rheumatoid arthritis. The study aims to understand the treatments safety, preliminary effectiveness, pharmacokinetics, pharmacodynamics, and immunogenicity. Participants will undergo a cycle that starts with lymphodepletion using fludarabine and cyclophosphamide, or cyclophosphamide alone if they have low blood cell counts. This is followed by three doses of NKX019. The dose escalation follows a 33 design to find the recommended dose for further study. The study includes one treatment group receiving NKX019 combined with lymphodepleting drugs to assess safety and tolerability. During the study, participants will be closely monitored for dose-limiting toxicities within the first 28 days and treatment-emergent adverse events throughout treatment and 30 days after. Assessments include safety evaluations, pharmacokinetic measurements, and immunogenicity testing up to two years after infusion. The study also tracks effects on background therapies and disease-specific outcomes. Overall participation may last up to two years, with regular visits and evaluations to monitor health and treatment response.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
12 locations
S

Actively Recruiting

Researchers are studying DB-1303BNT323, a biological drug, in a Phase 12a trial to evaluate its safety and tolerability in adults with advanced or metastatic malignant solid tumors that express HER2. The trial focuses on patients whose tumors are refractory to standard treatments or have no available standard options. This first-in-human study includes both a dose-escalation phase to find the maximum tolerated dose and a dose-expansion phase to further assess safety and explore efficacy in selected tumors. Participants receive DB-1303BNT323 intravenously once every three weeks at various dose levels, including a randomized comparison of doses during some expansion cohorts. Additional treatments may include ritonavir or itraconazole to assess drug interactions, and in some cases, DB-1303BNT323 is combined with Pertuzumab. The study is open-label and multicenter, with dosing continuing according to the protocols schedule. During the trial, participants undergo regular assessments including safety monitoring for adverse events, dose-limiting toxicities, and serious adverse events up to about one year post-treatment. Researchers measure tumor response using RECIST 1.1 criteria and evaluate pharmacokinetics and pharmacodynamics. Organ function, heart performance, and life expectancy are also monitored throughout this period. The estimated study completion is in October 2027.

Age: 18Years +All GendersPhase 1Phase 2
102 locations
P

Actively Recruiting

Researchers are conducting a Phase 12a clinical trial to evaluate the safety and tolerability of DB-1311BNT324 in adults with advanced solid tumors that have progressed after standard treatments or have no available standard options. The trial aims to find the maximum tolerated dose and recommended dose for further study, as well as explore preliminary antitumor activity in selected cancers including prostate cancer. The study is multicenter, open-label, and includes a drug-drug interaction sub-study to assess the effects of other medications on DB-1311. In Phase 1, participants receive escalating single doses of DB-1311BNT324 every three weeks to determine safety and optimal dosing. Phase 2a expands dosing to confirm safety and explore effectiveness of DB-1311 given alone or combined with hormone therapies such as enzalutamide or abiraterone in prostate cancer. Treatment cycles are repeated every 21 days via intravenous infusion. Some participants receive additional oral medications to study interactions. The trial includes various cohorts with different tumor types and prior treatment histories. Participants undergo multiple assessments including safety labs, vital signs, ECGs, heart function tests, and performance status evaluations throughout treatment and for about one year after. Tumor response is measured using standard criteria, along with pharmacokinetic and immunogenicity tests. Researchers monitor adverse events and serious events continuously. The total participation lasts up to approximately one year post-treatment to evaluate safety, dosing, and preliminary outcomes.

Age: 18Years +All GendersPhase 1Phase 2
107 locations
S

Actively Recruiting

Researchers are evaluating a new treatment approach for adults aged 18 to 75 years with newly diagnosed acute myeloid leukemia AML that has specific genetic changes in the NPM1, MLLKMT2A, or NUP98 genes. This phase Ib trial aims to find the best dose and assess the safety of the drug revumenib SNDX-5613 when combined with standard chemotherapy drugs daunorubicin and cytarabine. The study focuses on patients who can tolerate intensive chemotherapy and have untreated AML. Participants receive revumenib orally twice daily alongside daunorubicin given intravenously for 1 to 3 days and cytarabine given as a continuous infusion or intermittent intravenous infusion depending on the treatment phase. Treatment includes an induction phase, possible re-induction for persistent disease, and consolidation cycles repeated every 42 days up to three times if tolerated. During treatment, patients undergo heart function scans, bone marrow biopsies, and blood tests at scheduled times to monitor response and safety. Throughout the study, patients are closely monitored through clinical assessments, including pharmacokinetic studies of revumenib and evaluations of leukemia cell response. After completing treatment, participants are followed for up to two years or until relapse or death. Researchers measure the recommended dose for further study, complete response rates, and other important outcomes such as measurable residual disease and potential biomarkers related to treatment response.

Age: 18Years - 75YearsAll GendersPhase 1
23 locations

1-10 of 147

1